TP53 and acute myeloid leukemia: Finally, in a multicenter retrospective analysis of patients with therapy-related AML or AML-MRC, MRD negativity (based on MFC; n = 37) was achieved at a higher rate in patients with wild-type versus mutated TP53 (36% vs. 8%) [42].